Quick Answer
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. reported Diluted EPS of $2.91 per share (loss) for fiscal year 2025.
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$2.91 | -1555.0% |
| 2024 | $0.20 | -97.8% |
| 2023 | $9.22 | -2.7% |
| 2022 | $9.48 | +24.7% |
| 2021 | $7.60 | +5.6% |
| 2020 | $7.20 | +42.0% |
| 2019 | $5.07 | +9.7% |
| 2018 | $4.62 | +81.9% |
| 2017 | $2.54 | -21.4% |
| 2016 | $3.23 | +3.2% |
| 2015 | $3.13 | +17.7% |
| 2014 | $2.66 | +25.5% |
| 2013 | $2.12 | +5.5% |
| 2012 | $2.01 | -6.1% |
| 2011 | $2.14 | +139.8% |
| 2010 | -$5.38 | -409.2% |
| 2009 | $1.74 | +122.3% |
| 2008 | -$7.80 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $1.10 | -17.3% | +3.8% |
| June 30, 2025 | $1.06 | -39.1% | +112.0% |
| March 31, 2025 | $0.50 | -61.5% | -62.4% |
| September 30, 2024 | $1.33 | -21.3% | -23.6% |
| June 30, 2024 | $1.74 | -7.9% | +33.8% |
| March 31, 2024 | $1.30 | -35.3% | -23.1% |
| September 30, 2023 | $1.69 | -10.1% | -10.6% |
| June 30, 2023 | $1.89 | -11.3% | -6.0% |
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. showed a decrease of -1555.0% in Diluted EPS compared to the prior fiscal year.
- Over the 2008–2025 period, CHARLES RIVER LABORATORIES INTERNATIONAL, INC.’s diluted eps has grown by 62.7% (from $7.80 per share (loss) to $2.91 per share (loss)).
- The most recent figure is from CHARLES RIVER LABORATORIES INTERNATIONAL, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 18, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: